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Abstract
Background: Type 2 diabetes mellitus (T2DM) has been linked to a state of pre-clinical chronic inflammation
resulting from abnormalities in the innate immune pathway. Serum levels of pro-inflammatory cytokines and acute-
phase proteins, collectively known as ‘inflammatory network’, are elevated in the pre-, or early, stages of T2DM and
increase with disease progression. Genetic variation can affect the innate immune response to certain
environmental factors, and may, therefore, determine an individual’s lifetime risk of disease.
Methods: We conducted a cross-sectional study in 6,720 subjects from the TwinsUK Registry to evaluate the
association between 18 single nucleotide polymorphisms (SNPs) in five genes (TLR4, IL1A, IL6, TNFA, and CRP) along
the innate immunity-related inflammatory pathway and biomarkers of predisposition to T2DM [fasting insulin and
glucose, HDL- and LDL- cholesterols, triglycerides (TGs), amyloid-A, sensitive C-reactive protein (sCRP) and vitamin D
binding protein (VDBP) and body mass index (BMI)].
Results: Of 18 the SNPs examined for their association with nine metabolic phenotypes of interest, six were
significantly associated with five metabolic phenotypes (Bonferroni correction, P ≤ 0.0027). Fasting insulin was
associated with SNPs in IL6 and TNFA, serum HDL-C with variants of TNFA and CRP and serum sCRP level with SNPs in
CRP. Cross-correlation analysis among the different metabolic factors related to risk of T2DM showed several significant
associations. For example, BMI was directly correlated with glucose (r = 0.11), insulin (r = 0.15), sCRP (r = 0.23), LDL-C
(r = 0.067) and TGs (r = 0.18) but inversely with HDL-C (r = -0.14). sCRP was also positively correlated (P < 0.0001)w i t h
insulin (r = 0.17), amyloid-A (r = 0.39), TGs (r = 0.26), and VDBP (r = 0.36) but inversely with HDL-C (r = -0.12).
Conclusion: Genetic variants in the innate immunity pathway and its related inflammatory cascade is associated
with some metabolic risk factors for T2DM; an observation that may provide a rationale for further studying their
role as biomarkers for disease early risk prediction.
Background
Type 2 diabetes mellitus (T2DM) represents a significant
global health problem. It is estimated that six people die
every minute from the disease worldwide, a figure that will
soon make the disease one of the world’sm o s tp r e v a l e n t
causes of preventable mortality [1]. The incidence of
T2DM increases with age, obesity, physical inactivity and
unhealthy diet, and is elevated among certain
ethnocultural groups (Hispanics, Africans, and Aborigi-
nals). The disease rates are also currently increasing
among children [2,3]. T2DM is primarily caused by
impaired glucose tolerance (IGT), which leads to islet b-
cell dysfunction and their subsequent destruction. The
ensuing insulin deficiency as a result of b-cell dysfunction
impacts skeletal muscle, liver and adipose tissues [4].
Among individuals with IGT, both host (primarily genetic)
and environmental factors contribute to the progression of
this condition to insulin resistance to T2DM [5-9].
Within the last decade, a hypothesis was proposed to
explain the pathogenesis of T2DM by connecting the
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that results from abnormalities in innate immunity path-
ways [10,11]. Activation of innate immunity promotes
various inflammatory reactions that provide the body’s
first line of defense against microbial, chemical and phy-
sical injury, leading to damage repair, isolation of micro-
bial threats and restoration of tissue homeostasis
[12,13]. The systemic reaction of innate immunity,
known as the ‘acute-phase response’, is initiated when
exogenous threats, such as pathogens or certain dietary
factors, are detected by pattern-recognition receptors
such as toll-like receptors (e.g., TLR-4). The binding of
the exogenous molecules by TLR-4 triggers the release
of pro-inflammatory cytokines, like tumour necrosis fac-
tor (TNF)-a, interleukin (IL)-1b and IL-6 [14]. These
cytokines are derived primarily from activated macro-
phages and can directly enhance insulin resistance in
adipocytes, muscle and liver cells [15,16]. Activation of
macrophages towards an inflammatory phenotype
results in further cytokine synthesis and release [17,18].
Cytokines down-regulate major anabolic cascades
involved in insulin signalling and can, subsequently,
mediate adipocyte insulin resistance [17,18]. Ultimately,
this process contributes to a systemic disruption of insu-
lin homeostasis, leading to a status of impaired glucose
tolerance [19]. Cytokines also trigger the synthesis of
acute-phase inflammatory proteins such as C-reactive
protein (CRP) and serum amyloid-A. Pro-inflammatory
cytokines and acute-phase reactants, collectively known
as “inflammatory network”, play a role in initiating the
early stages of T2DM and are known to increase with
disease progression.
Genetic variation in the innate immunity pathway may
affect the extent of its activation and response upon
exposure to stimuli and, consequently, influencing the
lifetime risk of a given disease [20]. For example, genetic
variations along the innate immunity pathway may lead
to an altered response to dietary factors (e.g., fatty acids)
known to bind to TLR4 and initiate a downstream sig-
naling cascade leading to the synthesis of pro-inflamma-
tory cytokines [21]. As mentioned above, cytokines
contribute to initiating a state of impaired glucose toler-
ance, insulin resistance and a subsequent elevated risk
of T2DM. Elucidating the relationship between genetic
variation in innate immunity, inflammation, and bio-
chemical indices of T2DM is, therefore, critical to evalu-
ate the feasibility of employing innate immunity-related
genetic polymorphisms and inflammatory factors in pre-
dicting T2DM risk. Such knowledge might also provide
opportunities for the development of novel approaches
for disease prevention in the general population and vul-
nerable sub-populations, e.g., by using nutritional and/or
therapeutic factors that attenuate low-grade chronic
inflammation [21].
The present study was undertaken in an attempt to
explore the association between polymorphisms in var-
ious genes along the innate immunity-related inflamma-
tion cascade and the metabolic phenotypes associated
with risk of T2DM in order to evaluate their possible
utility as biomarkers in disease early risk prediction.
Methods
We conducted a cross-sectional analysis of the associa-
tion between factors that can be linked to early risk of
T2DM (as defined by the profile of risk-related meta-
bolic phenotypes) and genetic variation in candidate
genes along the innate immunity-related inflammatory
pathway, using data from the TwinsUK Registry [22].
Study subjects
The UK Adult Twin Registry (TwinsUK) is a database of
over 10,000 monozygotic and dizygotic twins aged 13 to
83 years, with a mean age of 48 years [22]. Initiated as
an investigation of osteoporosis and osteoarthritis, the
TwinsUK cohort evolved to include investigation of the
genetics of the metabolic syndrome and cardiovascular
disease as one of its main research goals [23]. The
cohort consists mostly of Caucasian female volunteers
from throughout the United Kingdom and Ireland who
were recruited via media campaigns [22]. This research
conformed to the ethical standards of the Helsinki
Declaration. The study protocol was approved by St.
Thomas’ Hospital Local Research Ethics Committee and
all participants gave written informed consent prior to
commencing the study. Recruitment and data collection
began in 1993, and nearly half of the cohort has been
clinically examined on at least two occasions [22]. The
specific data for this study were available through a col-
laboration initiated by the Public Health Agency of
Canada (A.B.) with McGill University (B.R.) and King’s
College London (T.D.S.). As such, the investigators had
restricted access to the selected genotypic and phenoty-
p i cd a t at h a tw e r ea n a l y z e di nt h i ss t u d y .W eo n l y
included cohort members aged sixteen years and older.
The population has been found to be representative of
singletons in the UK population with respect to preva-
lence of chronic disease and lifestyle characteristics [24].
Phenotypic and genotypic data
The serum biochemical indices and phenotypes of pre-
disposition to T2DM [fasting insulin and glucose, HDL-
cholesterol and LDL-C, triglycerides (TGs), the acute
phase proteins amyloid-A, highly sensitive C-reactive
protein (sCRP) and vitamin D binding protein (VDBP)
in addition to body mass index (BMI)] were obtained
from an extensive set of phenotypes available for the
TwinsUK study http://www.twinsUK.ac.uk. We did not
have an access to variables related to subject
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consider this factor in our analysis. Furthermore, study
subjects with evidence of diabetes (fasting glucose mea-
surement of > = 7 mmol/L) were excluded from the
analysis (oral glucose tolerance test data were not avail-
able) and this group is likely to include a substantial
fraction of those on lipid- or blood pressure-lowering
medications from the cohort. Furthermore, genome-
wide genotyping was performed in the population using
the Illumina Hap317K chip [25]. A selected set of SNPs
(or their proxies) was chosen from among the genotypes
available through this genome-wide association scan
(GWAS).
SNP identification
Eighteen SNPs were identified in five innate immunity
candidate genes (TLR4, IL1B, IL6, TNFA, and CRP). The
studied SNPs were selected based upon their previously
published effects on increasing the serum levels of a
range of inflammatory markers and their potential role
in the aetiology of T2DM [22,26-35]. We carried out an
association analysis on nine preselected metabolic mar-
kers with the following 18 SNPs [proxy]: IL1A (rs17561,
rs1609682 [rs10496444], rs2856838 [rs6746923],
rs1878321 [rs4848300]); IL-6 (rs1554606, rs2069837,
rs1474347 [rs7801406], rs2069827 [rs11766273]); TLR4
(rs1927906, rs1927914, rs4986790, rs1554973; TNFa
(rs3093662, rs1800630 [rs2259435]); and CRP
(rs2808630, rs1205 [rs2794520], rs1417938 [rs12093699],
rs3093059 [rs11265260]). Where the SNPs of interest
were not available on the Hap317K chip, we identified
proxy SNPs in strong linkage disequilibrium (LD) with
those of interest (>80%). LD was assessed by spectral
decomposition of pair-wise matrices (Additional file 1
Figure S1a - 1e), so that the 18 SNPs examined here
represented the variation of the above-identified 27 can-
didate loci within the five studied genes [36,37].
Statistical methods
All statistical analyses were performed using SAS soft-
ware (SAS Institute Inc., Cary, NC, USA.). The normal-
ity of the variables was assessed, and all phenotypes,
except HDL-C and LDL-C, were loge-transformed. Since
a large majority of our sample (>90%) consisted of
females, we did not stratify any of the analyses by sex.
Covariates considered for the multivariable linear regres-
sion analyses were age, sex, and BMI. If these covariates
were associated with the outcome phenotype in a uni-
variate analysis, they were included in a subsequent
multivariable analysis of association between SNP(s) and
phenotype(s). VDBP level was adjusted for age and
LDL-C, whereas TGs were adjusted for age and BMI.
The remainder of the covariates were all adjusted for
age, sex, and BMI. Where we observed multiple
significant associations between SNPs in a single gene
and a given outcome, we further investigated both the
independent effects of each SNP as well as the potential
joint effects of SNP combinations within the same gene
simultaneously. To test for independent effects, we con-
sidered multiple SNPs into the regression models to
observe whether significance remained. We created mul-
tiplicative interaction terms to test for significant joint
effects in two-way interactions between genotypes. As
our dataset included twin pairs, we accounted for non-
independence of observations using generalized estimat-
ing equations with a compound symmetry covariance
structure similar to a previously published study of a
twins cohort [38]. Spearman correlations were calculated
among all the adjusted metabolic indices of T2DM
examined in the present study. All statistical tests
assumed an additive effect of the allele using maximum-
likelihood linear regression analysis. In total, nine inde-
pendent statistical models were evaluated. Within each
model, 18 independent statistical tests were performed
at the selected loci. Thus, statistical significance was
declared at P ≤ 0.0027 by applying a Bonferroni correc-
tion (cutoff p-value = 0.05/18). The Bonferroni correc-
tion is very conservative and results in highly reduced
statistical power to detect differentiation among pairs of
sample collections [38]. The Benjamini and Yekutieli (B-
Y) false discovery rate (FDR) method is similar to the
Bonferroni correction, but it is a less conservative statis-
tical adjustment for multiple comparisons and was,
therefore, applied in the present study in addition to the
Bonferroni test (B-Y cutoff p-value = 0.014) [39]. The B-
Y critical value (B-Ycrit) is its own modified FDR mea-
sure and is calculated as B-Ycrit = a/∑(1/i). Where “a” =
0.05 and “I” v a r i e sf r o m1t o1 8r e p r e s e n t i n gt h en u m -
ber of tests conducted in a given regression model. For
alpha = 0.05 and i = 18, B-Ycrit = 0.014. Mean values for
the examined phenotypic measures, stratified by geno-
type for each of the 18 selected SNPs, as well as minor
allele frequencies (MAF), are presented in Additional
file 2, Table S1.
Results
The clinical characteristics of the study subjects (n =
6,720) are summarized in Table 1. The age of the study
subjects ranged between 16 and 83 years. The majority
of the subjects were female (90.3%). The overall BMI for
the cohort was 25.2 kg/m
2, with 53.7% of the subjects
showing normal BMI measures between 18.5 and 24.9
kg/m
2. All serum biochemical indices of predisposition
to T2DM were, on average, within the normal clinical
range.
Significant associations between genotypes of the
selected SNPs and metabolic phenotypes are presented
in Table 2. Of the 18 SNPs examined against each of
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strated a significant association with one or more phe-
notype after B-Y correction (p < 0.014). The specific
associations were between SNPs in IL6, TNFA and CRP
and fasting insulin, TGs, HDL-C and sCRP. After Bon-
ferroni adjustment (p ≤ 0.0027), the only remaining
associations were between the SNPs in CRP and sCRP.
Each additional allele of the CRP rs1205 was associated
with 39.2% (95%CI: 29.5-47.6%) decrease in serum CRP
level while each additional allele of CRP rs1417938 was
associated with 67.3% (95%CI: 44.5-93.8%) increase in
serum CRP level. The independent effects of these two
SNPs on serum CRP level remained significant after
adjustment for each other (prs1205 = 0.0002; prs1417938 =
<0.0001).
In order to identify the association between a set of
inflammatory markers and acute phase proteins (sCRP,
amyloid-A, and VDBP) and the serum biochemical
indices of predisposition to T2DM (fasting insulin and
glucose, HDL-C, LDL-C, and TGs, as well as BMI), a
cross-correlation analysis was carried out between these
factors as shown in Figure 1. sCRP was significantly (p
< 0.0001) correlated with increased levels of fasting
insulin (r =0 . 1 7 ) ,a m y l o i d - A( r =0 . 4 0 ) ,T G s( r =0 . 2 6 ) ,
and VDBP (r = 0.36) and with higher BMI (r = 0.23, p<
0.0001) but with lower levels of HDL-C (r = -0.12, p<
0.0001). As expected, circulating levels of HDL-C were
inversely correlated with fasting insulin (r = -0.15, p<
0.0001), LDL-C (r = -0.05, p = 0.024)a n dT G s( r =
-0.33, p < 0.0001). Furthermore, BMI was linked to ele-
vated serum levels of fasting glucose (r =0 . 1 1 ,p<
0.0001)a n di n s u l i n( r =0 . 1 5 ,p < 0.0001), LDL-C (r =
0.067, p = 0.0022), VDBP (r = 0.048, p = 0.049)a n d
TGs (r =0 . 1 8 ,p < 0.0001) and with lower serum HDL-
C( r = -0.14, p < 0.0001).
Discussion
We presented evidence for several associations between
polymorphisms in various genes along the innate immu-
nity-related inflammation cascade and the metabolic
phenotypes associated with risk of T2DM. Several lines
of evidence suggest a role for inflammation in regulating
Table 1 Characteristics of the study subjects from the
TwinsUK cohort
Measure n Mean ± SE
2 Range
Age (years) 6,720 46.2 ± 0.16 16.1 - 83.8
Sex
Male 653 9.7%
Female 6,067 90.3%
Fasting glucose (mmol/L) 6,623 4.6 ± 0.01 2.1 - 6.7
Triglycrides (mmol/L) 5,541 1.1 ± 0.01 0.15 - 8.9
Fasting Insulin (μIU/ml) 2,414 11.9 ± 0.31 2 - 177
LDL-C (mmol/L) 1,780 3.3 ± 0.02 0.3 - 6.9
HDL-C (mmol/L) 4,878 1.5 ± 0.01 0.2 - 3.1
sCRP (mg/L) 5,464 3.1 ± 0.09 0.0 - 161
Amyloid-A (mg/L) 360 6.7 ± 0.41 2 - 91
VDBP (ng/L) 1,730 301 ± 1.23 190 - 602
BMI (Kg/m
2) 4,710 25.2 ± 0.07 13.2 - 52.4
1Study population excluded subjects with fasting glucose of ≥ 7 mmol/L (i.e.,
possible diabetics) and those under 16 years of age.
2Values represent unadjusted mean ± standard error of n subjects.
Table 2 Association between a selected set of SNPs along the innate immunity-related inflammatory pathway and a
number of metabolic phenotypes related to risk of type II diabetes mellitus
Metabolic Markers
1
Insulin
2,3 Triglycerides
2,4 HDL-C
4 sCRP
2,3 VDBP
2
Gene SNP (Proxy) b (p) Model
n
b (p) Model
n
b (p) Model
n
b (p) Model
n
b (p) Model
n
IL6 rs1554606 0.0574
(0.0103)
3,039
rs1474347
(rs7801406)
-0.155
(0.0078)
2,489
TNFA rs3093662 0.316
(0.0034)
1,583
rs1800630
(rs2259435)
-0.0883
(0.0068)
1,945
CRP rs1205 (rs2794520) -0.498
(<0.0001)
5
1,959
rs1417938
(rs12093699)
0.0699
(0.0079)
1,946 0.515
(<0.0001)
5
1,951 0.0383
(0.0134)
1,082
1Values represent regression coefficient (b) and p-values in parentheses. Metabolic phenotypes and SNPs with no significant association were not presented.
Bonferroni correction level of statistical significance is p < 0.0027; B-Y correction level of statistical significance is p < 0.014.
2Natural logarithm of measures.
3Adjusted for BMI, age and sex.
4Adjusted for BMI and sex.
5Associations remained significant (p < 0.05) after adjustment for other SNPs in the gene.
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Compared to healthy individuals, subjects with T2DM
risk factors such as obesity, hyper-triglyceridemia, or
low HDL-C exhibit elevated serum levels of pro-inflam-
matory cytokines and acute-phase reactants [10].
Furthermore, it is well established that levels of inflam-
matory markers exhibit a gradual increase as T2DM
develops and progresses to its complications. Initial high
circulating levels of pro-inflammatory cytokines were
also thought to contribute, at least partly, to the subse-
quent manifestation of disease [40-45].
Genetic variants in innate immunity-related inflamma-
tory pathways may affect metabolic phenotypes asso-
ciated with T2DM risk, and therefore contribute to
disease pathogenesis. Indeed, a number of studies have
noted that inherited variants in genes encoding for this
pathway are associated with T2DM and other cardio-
metabolic disorders [46-50]. We observed several asso-
ciations between SNPs in genes along the innate immu-
nity pathway and metabolic and phenotypic indices
related to the risk of T2DM (Table 2). For example,
fasting insulin levels were associated with SNPs in IL6
and TNFA, whereas HDL-C was associated with variants
in TNFA and CRP (Table 2). The strongest associations
observed in the present study were between two variants
in CRP and serum levels of sCRP (p < 0.0001). The CRP
variant rs1205 was inversely associated with sCRP, while
rs1417938 exhibited a direct association with the serum
levels of sCRP. CRP rs1417938 was also positively asso-
ciated with circulating HDL-C and VDBP.
Previous reports have demonstrated a significant asso-
ciation between variants in the genes assessed here and
serum levels of inflammatory markers, metabolic pheno-
types associated with T2DM risk, and/or disease inci-
dence (for review see 21). For example, genetic variants
in the promoter region of the IL6 gene (rs1800795 and
rs1800796; both are in LD with the IL6 SNPs examined
here) have been linked with susceptibility to T2DM
[26]. Furthermore, the association of polymorphisms in
the TNFA with T2DM and its related complications has
Amyloid
sCRP
HDL
Insulin
LDL
TGs
VDBP
BMI
(1)
(2)
(3) (4) (5)
(6) (7)
(8) (9) (10) (11) (12) (13)
(14) (15) (16) (17)
(18) (19) (20) (21) (22) (23) (24)
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
(12)
(13)
(14)
(15)
(16)
(17)
(18)
(19)
(20)
(21)
(22)
(23)
(24)
r=0.3939, p<0.0001 (n=320)
r=-0.1239, p<0.0001 (n=2,996)
r=0.2971, p<0.0001 (n=2,514)
r=0.1664, p=<0.0001 (n=2,588)
r=-0.1498, p=<0.0001 (n=2,356)
r=0.08054, p=0.0006 (n=1,819)
r=-0.05104, p=0.0241 (n=1,952)
r=0.1383, p<0.0001 (n=3,039)
r=0.1172, p=0.0385 (n=312)
r=0.2592, p=<0.0001 (n=2,954)
r=-0.3341, p=<0.0001 (n=3,184)
r=0.2060, p<0.0001 (n=2,311)
r=0.2217, p<0.0001 (n=1,965)
r=0.1632, p=0.0219 (n=197)
r=0.3649, p<0.0001 (n=1,567)
r=0.06585, p=0.0205 (n=1,238)
r=0.2088, p<0.0001 (n=1,569)
r=0.1062, p<0.0001 (n=3,542)
r=0.2308, p<0.0001 (n=3,332)
r=-0.1382, p<0.0001 (n=3,240)
r=0.1525, p<0.0001 (n=2,595)
r=0.06671, p=0.0022 (n=2,104)
r=0.1768, p<0.0001 (n=3,207)
r=0.04842, p=0.0494 (n=1,647)
Figure 1 Cross-correlation analysis between serum biochemical indices and metabolic risk factors of T2DM. Only significant correlations
are highlighted and numbered. For each significant correlation, Pearson’s correlation coefficients (r), p-values and sample sizes are shown in
parentheses.
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rs1800629 and rs361525, both located in the TNFA pro-
moter region, have been implicated in the predisposition
to T2DM [27]. The minor allele of rs1800629 has been
linked to increased TNFA transcriptional activity [51],
whereas rs361525 is located in a repressor site of the
gene [52]. In this study, we noted a strong association
between the TNFA variant rs3093662 and fasting insu-
lin. Each additional allele of TNFA rs3093662 was found
to be associated with about 37.1% (95%CI: 11.0-69.5%)
increase in serum fasting insulin levels. Although TNFA
rs3093662 was previously linked to a higher serum level
of TNF-a [53], to our knowledge the present results is
the first reported link between this variant and elevated
levels of serum insulin. This observation substantiates a
further investigation for the role of the TNFA gene var-
iants in T2DM risk and progression.
A number of SNPs in the CRP gene have been linked
to elevated levels of serum sCRP [32], insulin sensitivity
[33], and T2DM [34,35]. As noted previously, in the
present study we observed an association between two
CRP variants and sCRP (rs1205 and rs1417938, Table
2). These variants markedly modulated the serum levels
of sCRP where each additional allele of rs1205 conferred
approximately 40% lowering in serum sCRP while an
additional allele of rs1417938 resulted in about 67%
increase in sCRP. These results are in line with observa-
tions indicating a strong impact of local SNPs of the
CRP gene on plasma CRP levels although no direct evi-
dence were established to demonstrate that these geneti-
cally controlled CRP elevations may contribute to
cardiometabolic phenotypes [54]. However, several stu-
dies have reported that serum CRP, particularly in
T2DM, can be influenced additively via the interaction
between SNPs in IL6 and CRP [54-57]. Furthermore, a
number of GWAS report have been carried out in order
to identify loci that may modulate the serum levels of
the metabolic indices such as LDL-C, HDL-C, CRP,
TGs, etc. that were examined in this study [58-60]. Of
the variants identified in these studies, only the CRP
SNP rs2794520, which is in LD with rs1205, was exam-
ined in the present study and, as discussed earlier, was
f o u n dt op l a yar o l ei na t t e n u a t i n gt h es e r u ml e v e l so f
sCRP (Table 2).
Although several genetic variants were implicated in
risk of T2DM, it is not clear whether these variants are
themselves causal or in LD with other causal SNPs. A
reason for not taking into account (Bonferroni correc-
tion) the number of phenotypes may be that the pheno-
types are strongly correlated with each other. Further
studies, such as pathway analyses, are required to under-
stand the functional consequences of the present find-
ings and to clarify the causal relationships between the
studied (and other) variants along the innate-immunity-
related inflammation and the risk of T2DM. This is
essential with the present findings, particularly where
several of the outcomes of association analysis (Table 2)
were found to correlated with one another. In addition,
identification of additional SNPs or copy number varia-
tions (CNVs) of inflammation-related genes, their fre-
quencies and their association with risk of T2DM will
assist in further clarifying the genetic basis of the disease
and in designing strategies for early risk prediction.
Gene-gene interactions may present a potential to partly
explain phenotypic variability and disease risk. Although
we only investigated one such instance in this analysis
(i.e., the interaction between CRP polymorphisms affect-
ing circulating sCRP levels), with improved methodolo-
gies for large scale gene-gene interaction analysis,
additional analyses may prove valuable in elucidating
mechanisms by which T2DM develops, as well as in
improving risk prediction [61]. Gene-environment inter-
actions, and in particular gene-diet interactions, may
also contribute to inter-individual variability in disease
risk, and the potential modifying effects of nutrients
with anti-inflammatory properties, such as vitamin D,
on the relationship between genetic variants and meta-
bolic phenotypes associated with increased T2DM risk
are being currently investigated. A potential limitation
of this study stems from its focus on a selected panel of
SNPs without investigating a more comprehensive set of
genome-wide variants in association with the metabolic
trait of interest. This candidate gene approach is known
to have a limited power in identifying novel loci com-
pared to a genome-wide association scan (GWAS).
Moreover, investigating only a few SNPs along a parti-
cular pathway (e.g., innate immunity-related inflamma-
tion as investigated here) will preclude the assessment
of interactions between multiple related pathways on
disease etiology (e.g., various metabolic and phenotypic
indices related to risk of T2DM). Our choice, however,
of SNPs along the inflammatory cascade was substan-
tiated from numerous reports implicating this signaling
pathway in susceptibility to T2DM [22,26-35].
The results of the present study demonstrate inter-
correlations between various metabolic phenotypes that
are linked to T2DM risk. These correlations include
associations between biomarkers of inflammation such
as sCRP (whose serum levels increase as a downstream
effect of the action of pro-inflammatory cytokines) and
dysregulation of lipid metabolism, such as increased
fasting glucose and insulin, decreased HDL-C and
increased serum TGs (Figure 1). The observed correla-
tions between the assessed metabolic phenotypes of
T2DM risk are in agreement with existing knowledge
with respect to the clinical interaction between these
biomarkers [62,63]. Furthermore, the inter-correlation
between the different metabolic and phenotypic indices
Arora et al. BMC Medical Genetics 2011, 12:95
http://www.biomedcentral.com/1471-2350/12/95
Page 6 of 9of disease risk provides an integrated view of the T2DM
risk profile as being determined by the dysregulation of
several physiologic pathways, such as glucose metabo-
lism, lipid metabolism, and the inflammatory response.
This view is also supported by our observation that sev-
eral of the SNPs assessed here were associated with phe-
notypes from multiple metabolic pathways. In this
respect, we observed a significant correlation between
increased BMI and biochemical indices of T2DM (e.g.,
measures of glucose, lipid metabolism, and inflammatory
markers; see Figure 1). This result is agreement with
previous research implicating obesity in the predisposi-
tion to T2DM [7,44] and suggest the use of BMI as a
robust surrogate of cardiometabolic dysfunction. Exten-
sive experimental, clinical and epidemiological studies
have previously linked obesity to the activation of
inflammatory signalling pathways and to the subsequent
manifestations of T2DM [7,64,65]. This observation
further suggests a possible role of the innate immunity-
related inflammatory pathway in the etiology of T2DM
and implicates factors that attenuate inflammation as an
approach for disease intervention [21].
Conclusions
In conclusion, our results support previous evidence
demonstrating that genetic variants along innate
immune-related inflammatory pathways are associated
with metabolic risk factor phenotypes for T2DM. This
research contributes toward the knowledge base for bio-
marker discovery for early T2DM detection. The find-
ings from this study also highlight multiple associations
between biochemical indices of T2DM and suggest an
underlying network of various pathways that become
dysregulated during the onset and progression of the
disease.
Additional material
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